VAXELIS videos and resources to support your practice

Resources You Need to Help Your Office Transition to VAXELIS™ (Diphtheria and Tetanus Toxoids and Acellular Pertussis, Inactivated Poliovirus, Haemophilus b Conjugate and Hepatitis B Vaccine)

VAXELIS Video Resources

Video: What Is VAXELIS™ (Diphtheria and Tetanus Toxoids and Acellular Pertussis, Inactivated Poliovirus, Haemophilus b Conjugate and Hepatitis B Vaccine)?Play Icon

What is VAXELIS?

Video: Discover How 2-3 Fewer Pediatric Vaccinations May Reduce the Shot Burden for Children and ParentsPlay Icon

Why Consider VAXELIS?

Video: Transitioning Your Practice to VAXELIS™ (Diphtheria and Tetanus Toxoids and Acellular Pertussis, Inactivated Poliovirus, Haemophilus b Conjugate and Hepatitis B Vaccine)Play Icon

Transitioning to VAXELIS

What is VAXELIS? - A conversation with Dr. Wolynn

Learn about VAXELIS, the first-and-only FDA approved hexavalent vaccine5

Transcript:

Hello, I’m Dr. Todd Wolynn, and I’ve been a pediatrician for 26 years in Pittsburgh, Pennsylvania.

There haven’t been many pediatric combination vaccines introduced in the last decade, which is why I’m excited to talk to you about VAXELIS, an FDA-approved hexavalent vaccine.2,5,12

Let me tell you a bit about VAXELIS.

  • VAXELIS is a vaccine indicated for active immunization to prevent diphtheria, tetanus, pertussis, poliomyelitis, hepatitis B, and invasive disease due to Haemophilus influenzae type b, or Hib. VAXELIS is approved for use as a 3-dose series in children 6 weeks through 4 years of age (prior to the 5th birthday).

VAXELIS can help simplify the execution of the infant vaccination series with 2 to 3 fewer shots compared to pentavalent vaccines in combination with hepatitis B or Hib vaccines.2,3,4,12

As the first-and-only hexavalent approved in the US, VAXELIS is an exciting development in the combination vaccine category.5 Merck and Sanofi Pasteur—two of the most trusted and established immunization experts in the world—partnered to create VAXELIS.5

  • Do not administer VAXELIS to anyone with a history of severe allergic reaction to a previous dose of VAXELIS, any ingredient of VAXELIS, or any other diphtheria toxoid, tetanus toxoid, pertussis-containing vaccine, inactivated poliovirus vaccine, hepatitis B vaccine, or Hib vaccine.
  • Do not administer VAXELIS to anyone with a history of encephalopathy within 7 days of a pertussis-containing vaccine with no other identifiable cause.
  • Do not administer VAXELIS to anyone with a history of progressive neurologic disorder until a treatment regimen has been established and the condition has stabilized.
  • Additional Important Safety Information will be provided during this video.

Since VAXELIS is the first-and-only FDA-approved hexavalent vaccine,5 there are a few things to look forward to. For instance, VAXELIS minimizes the number of injections over the series of primary visits at 2, 4, and 6 months of age. That means patients and their parents can experience the benefits of 2 to 3 fewer shots compared to pentavalent vaccines in combination with hepatitis B or Hib vaccines.2,3,4,12

  • Carefully consider benefits and risks before administering VAXELIS to persons with a history of fever of 40.5° Celsius or higher (that’s 105° Fahrenheit or higher), hypotonic-hyporesponsive episode, or persistent, inconsolable crying lasting 3 or more hours within 48 hours after a previous pertussis-containing vaccine; and/or seizures within 3 days after a previous pertussis-containing vaccine.
  • If Guillain-Barré syndrome occurred within 6 weeks of receipt of a prior vaccine containing tetanus toxoid, the risk for Guillain-Barré syndrome may be increased following VAXELIS.
  • Apnea following intramuscular vaccination has been observed in some infants born prematurely. Consider the individual infant’s medical status and potential benefits and possible risks of intramuscular vaccination in deciding when to administer VAXELIS to an infant born prematurely.

There are potential practice benefits to look forward to with VAXELIS as well. VAXELIS is available in 0.5 mL single-dose vials or 0.5 mL ready-to-use prefilled syringes with no reconstitution needed. It’s also preservative-free. Fewer shots needed may help reduce vaccine prep time, administration errors7 and tasks associated with billing and coding—because it requires one NDC instead of two.

  • Vaccination with VAXELIS may not protect all individuals.
  • The solicited adverse reactions 0-5 days following any dose were irritability at 55% or more, crying at 45% or more, injection site pain at 44% or more, somnolence at 40% or more, injection site erythema at 25% or more, decreased appetite at 23% or more, fever of 38.0° Celsius or higher at 19% or more, injection site swelling at 18% or more, and vomiting at 9% or more.

All in all, there are many good reasons for a pediatric practice to consider transitioning to VAXELIS.

Before administering VAXELIS, please read the accompanying Prescribing Information. The Patient Information also is available.

Why Consider VAXELIS? - A conversation with Dr. Wolynn

Discover how 2 to 3 fewer shots across the infant and primary series may reduce the shot burden for patients and parents2,3,4,12

Transcript:

Hello, I’m Dr. Todd Wolynn. As a pediatrician in practice for 26 years, I’m considering VAXELIS, the first-and-only FDA-approved hexavalent vaccine, for my practice.5

VAXELIS is worth considering whether you’re a part of an individual pediatric practice or in a network or other larger health care system.

Let’s talk about why you should consider VAXELIS.

  • VAXELIS is a vaccine indicated for active immunization to prevent diphtheria, tetanus, pertussis, poliomyelitis, hepatitis B, and invasive disease due to Haemophilus influenzae type b, or Hib. VAXELIS is approved for use as a 3-dose series in children 6 weeks through 4 years of age (prior to the 5th birthday).

Practices should consider incorporating VAXELIS because it requires 2 to 3 fewer shots across the infant vaccination series compared to pentavalent vaccines, which do not contain either a hepatitis B or Hib component, depending on the brand. This can mean less of a shot burden for patients and parents.2,3,4,12

Fewer shots may also help improve efficiencies and reduce administrative tasks.7

  • Do not administer VAXELIS to anyone with a history of severe allergic reaction to a previous dose of VAXELIS, any ingredient of VAXELIS, or any other diphtheria toxoid, tetanus toxoid, pertussis-containing vaccine, inactivated poliovirus vaccine, hepatitis B vaccine, or Hib vaccine.
  • Do not administer VAXELIS to anyone with a history of encephalopathy within 7 days of a pertussis-containing vaccine with no other identifiable cause.
  • Do not administer VAXELIS to anyone with a history of progressive neurologic disorder until a treatment regimen has been established and the condition has stabilized.
  • Additional Important Safety Information will be provided during this video.

VAXELIS may help reduce vaccination prep time and errors associated with administration.7,13 It could help simplify the execution of the infant immunization schedule and vaccination process.2,3,4,12 And with fewer shots needed, VAXELIS may also help improve vaccination compliance in the infant series.6,13,14

  • Carefully consider benefits and risks before administering VAXELIS to persons with a history of fever of 40.5° Celsius or higher (that’s 105° Fahrenheit or higher), hypotonic-hyporesponsive episode, or persistent, inconsolable crying lasting 3 or more hours within 48 hours after a previous pertussis-containing vaccine; and/or seizures within 3 days after a previous pertussis-containing vaccine.
  • If Guillain-Barré syndrome occurred within 6 weeks of receipt of a prior vaccine containing tetanus toxoid, the risk for Guillain-Barré syndrome may be increased following VAXELIS.

Before deciding to make the transition to VAXELIS, there are a few questions an office might want to ask:

  • What is the safety and immunogenicity profile of VAXELIS?
  • What could a hexavalent schedule mean for my patients and their parents?
  • How might VAXELIS impact the day-to-day efficiencies of my practice?
  • And how smoothly will we be able to make this transition?

To find information to help answer these questions, please visit Vaxelis.com.

  • Apnea following intramuscular vaccination has been observed in some infants born prematurely. Consider the individual infant’s medical status and potential benefits and possible risks of intramuscular vaccination in deciding when to administer VAXELIS to an infant born prematurely.
  • Vaccination with VAXELIS may not protect all individuals.
  • The solicited adverse reactions 0-5 days following any dose were irritability at 55% or more, crying at 45% or more, injection site pain at 44% or more, somnolence at 40% or more, injection site erythema at 25% or more, decreased appetite at 23% or more, fever of 38.0° Celsius or higher at 19% or more, injection site swelling at 18% or more, and vomiting at 9% or more.

Learn more about what 2-3 fewer shots in the infant series can mean for your patients, their parents, and your practice. Visit Vaxelis.com to see the safety and immunogenicity profile of VAXELIS, the hexavalent vaccine schedule, information about how VAXELIS can impact the day-to-day efficiencies of your practice, and more.

Don’t forget to visit Vaxelis.com to learn more. And take a look at VaxelisTransition.com for resources that can assist you with the transition process. You may find that incorporating VAXELIS is the right choice.

Before administering VAXELIS, please read the accompanying Prescribing Information. The Patient Information also is available.

Transitioning to VAXELIS - A conversation with Dr. Wolynn

Tips and tools for a more successful transition

Transcript:

Hello, I’m Dr. Todd Wolynn. As a pediatrician, I’m considering VAXELIS for my practice. I’d like to talk to you about steps you can take and the resources available to you if you’re considering VAXELIS.

  • VAXELIS is a vaccine indicated for active immunization to prevent diphtheria, tetanus, pertussis, poliomyelitis, hepatitis B, and invasive disease due to Haemophilus influenzae type b, or Hib. VAXELIS is approved for use as a 3-dose series in children 6 weeks through 4 years of age (prior to the 5th birthday).

To prepare for a transition to VAXELIS, there are a few basic steps that an office might want to consider. These include assessing the overall needs of your practice, evaluating how VAXELIS may impact the administration of the infant vaccination schedule, taking stock of your current inventory, and discussing VAXELIS and its potential risks and benefits with your patients’ parents or caregivers and your office staff.

  • Do not administer VAXELIS to anyone with a history of severe allergic reaction to a previous dose of VAXELIS, any ingredient of VAXELIS, or any other diphtheria toxoid, tetanus toxoid, pertussis-containing vaccine, inactivated poliovirus vaccine, hepatitis B vaccine, or Hib vaccine.
  • Do not administer VAXELIS to anyone with a history of encephalopathy within 7 days of a pertussis-containing vaccine with no other identifiable cause.
  • Do not administer VAXELIS to anyone with a history of progressive neurologic disorder until a treatment regimen has been established and the condition has stabilized.
  • Additional Important Safety Information will be provided during this video.

There are a few key resources that will help you prepare for a transition to VAXELIS.

The first is the VAXELIS Transition Tool website, which can be found at VaxelisTransition.com. Office staff can easily navigate the site and find useful information about the VAXELIS vaccination schedule, billing and coding, storage information, administration, and ordering. All the resources are easy to access, and most can be downloaded and printed to use as references around the office.

The site also includes a downloadable and printable Patient Education Brochure that a practice can give to parents to help inform them about VAXELIS.

Vaxelis.com is another resource. This website has clinical information needed to better inform office staff about VAXELIS.

Here is some additional Important Safety Information.

  • Carefully consider benefits and risks before administering VAXELIS to persons with a history of fever of 40.5° Celsius or higher (that’s 105° Fahrenheit or higher), hypotonic-hyporesponsive episode, or persistent, inconsolable crying lasting 3 or more hours within 48 hours after a previous pertussis-containing vaccine; and/or seizures within 3 days after a previous pertussis-containing vaccine.
  • If Guillain-Barré syndrome occurred within 6 weeks of receipt of a prior vaccine containing tetanus toxoid, the risk for Guillain-Barré syndrome may be increased following VAXELIS.
  • Apnea following intramuscular vaccination has been observed in some infants born prematurely. Consider the individual infant’s medical status and potential benefits and possible risks of intramuscular vaccination in deciding when to administer VAXELIS to an infant born prematurely.
  • Vaccination with VAXELIS may not protect all individuals.
  • The solicited adverse reactions 0-5 days following any dose were irritability at 55% or more, crying at 45% or more, injection site pain at 44% or more, somnolence at 40% or more, injection site erythema at 25% or more, decreased appetite at 23% or more, fever of 38.0° Celsius or higher at 19% or more, injection site swelling at 18% or more, and vomiting at 9% or more.

Now that I’ve provided some information about the resources available to you, you should feel confident about preparing to transition to VAXELIS. Visit Vaxelis.com and VaxelisTransition.com to get started today.

Before administering VAXELIS, please read the accompanying Prescribing Information. The Patient Information also is available.

Transition Tool

Resources to support your practice’s transition to a hexavalent vaccine regimen.

Contracting Site

Signing up for a contract through Sanofi Pasteur, plus ordering, billing and coding.

Patient Education Brochure

Information for parents and caregivers about the risks and benefits of VAXELIS.

Download brochure